Glipizide
Glipizide is one of 8,063 medications in the MedPlain dataset. Key details — Brand name: Glipizide; Generic name: GLIPIZIDE; Drug class: Sulfonylurea [EPC].
| Brand name | Glipizide |
|---|---|
| Generic name | GLIPIZIDE |
| Drug class | Sulfonylurea [EPC] |
| Manufacturer | ST. MARY'S MEDICAL PARK PHARMACY |
| Used for | 1 INDICATIONS AND USAGE Glipizide extended-release tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Glipizide extended-release tablets is a sulfonylurea indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus Limitations of Use: Not for treatment of type 1 diabetes or diabetic ketoacidosis 1.1 Limitations of Use Glipizide extended-release tablets are not recommended for the treatment of type 1 diabetes mellitus or diabetic ketoacidosis. |
| Dosage | 2 DOSAGE AND ADMINISTRATION Recommended starting dose is 5 mg once daily. Dose adjustment can be made based on the patient’s glycemic control. Maximum recommended dose is 20 mg once daily ( 2.1 ). Administer with breakfast or the first meal of the day ( 2.1 ). For combination therapy with other blood-glucose-lowering agents, initiate the agent at the lowest recommended dose, and observe patients for hypoglycemia ( 2.2 ). 2.1 Recommended Dosing Glipizide extended-release tablets should be adminis |
| Active ingredient(s) | GLIPIZIDE |
| Route | ORAL |
| Official label | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0ccc17ca-fff8-0449-e063-6294a90af36d |